The FDA has accepted for filing the registration application for Sublinox™
Meda AB acquired the exclusive world-wide commercialization rights for SublinoxTM on April 14, 2008. “This FDA’s acceptance increases the chances for a registration approval during 2009”, said Anders Lönner, CEO of Meda.
The data supporting the product includes a clinical study in insomnia patients that was completed in October 2007. That study showed that SublinoxTM induced sleep 30 percent earlier compared to Ambien® and that patients remained asleep throughout the night with comparable safety.
“This is an important first step to get SublinoxTM out on the world markets” said Torbjörn Bjerke, Orexo’s President and CEO.
For more information, please contact:
Orexo AB Claes Wenthzel, Executive Vice President & CFO
Tel: +46 (0)18-780 88 44, E-mail: firstname.lastname@example.org
Meda AB Anders Larnholt, Vice President Investor Relations
Tel: +46 (0)709-458 878, E-mail: email@example.com
Orexo is a pharmaceutical company, focusing on development of new, patented drugs by combining well-documented substances with innovative technologies, and the development of new treatments for respiratory and inflammatory diseases. Orexo has a broad and competitive late-stage product portfolio, including two marketed products, five products in clinical phase and two in registration phase. Orexo has head office in Uppsala and is listed on the OMX Nordic Exchange Stockholm, Small Cap (ticker: ORX). www.orexo.com
MEDA AB (publ) is an international specialty pharma company that concentrates on marketing and market-adapted product development. Acquisitions and long-term partnerships are fundamental factors that drive the company’s strategy. Meda is represented by its own organisations in 26 countries and has more than 1 500 employees within marketing and sales. Meda’s products are sold in approximately 120 countries world-wide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit www.meda.se.